useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
By assessing genetic variants in peptide receptor pathways, metabolic regulation, and inflammatory responses, the test supports more personalized clinical conversations about symptom risk and treatment optimization strategies tailored to individual biology
In this case, semaglutide mimics the hormone glucagon-like peptide-1 (GLP-1), which is released in the gut during eating to signal a feeling of satiation, so it follows that its now implicated in moderating similar feelings of stress and reward involved in alcohol use
Learn more about metabolic health and virtual care at Carebridge Medical: www.mycarebridgemed.com #MetabolicHealth #ObesityMedicine #GLP1 #WeightLossMedicine To view or add a comment, sign in CagriSema vs Tirzepatide (REDEFINE 4): strong weight loss, but an important endpoint miss Novo Nordisk has announced headline results from the open-label phase 3 REDEFINE 4 trial comparing CagriSema (cagrilintide + semaglutide) vs tirzepatide 15 mg in obesity
